Dose validation and study design criteria in current cimetidine studies.

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Duodenal ulcers are common gastrointestinal conditions requiring effective treatment.
• Optimizing medication dosage is crucial for therapeutic success and patient comfort.

Purpose of the Study:

• To compare the efficacy of different cimetidine dosages (400 mg, 800 mg, 1600 mg) against placebo for acute duodenal ulcer healing.
• To evaluate the impact of smoking and ulcer size on duodenal ulcer healing rates.
• To assess the effectiveness of cimetidine in providing pain relief for duodenal ulcer patients.

Main Methods:

• A large dose validation study involving patients with acute duodenal ulcers.
• Comparison of cimetidine at 400 mg, 800 mg, and 1600 mg dosages versus placebo, administered at bedtime.
• Assessment of ulcer healing rates and pain relief at various time points.
• Analysis of the influence of smoking status and ulcer size on treatment outcomes.

Main Results:

• Cimetidine 800 mg demonstrated superior ulcer healing rates (75%) compared to placebo (45%) and 400 mg (60%) (P < 0.05).
• No significant difference in healing was observed between 800 mg (75%) and 1600 mg (81%) dosages.
• Smoking and larger ulcer size were negatively correlated with ulcer healing.
• Cimetidine 800 mg provided significant pain relief, superior to placebo and 400 mg during the initial week of treatment.

Conclusions:

• Cimetidine 800 mg at bedtime is the most appropriate dosage for acute duodenal ulcer therapy.
• This dosage effectively combines optimal ulcer healing with maximum pain relief.
• Factors such as smoking and ulcer size should be considered in managing duodenal ulcer patients.